TRIM59-IFT80: A Potential Drug Target and Biomarker (G100174949)

Target Name: TRIM59-IFT80

NCBI ID: G100174949

TRIM59-IFT80

Other Name(s): TRIM59-IFT80 variant 1 | TRIM59-IFT80 variant 3 | TRIM59-IFT80 protein | IFT80-L

TRIM59-IFT80: A Potential Drug Target and Biomarker

TRIM59-IFT80, also known as NEDD8, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. NEDD8 is a small molecule that has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and repair, among others.

One of the unique features of TRIM59-IFT80 is its ability to interact with multiple protein partners, including histone-modifying enzymes and non-histone modifiers. This interaction between TRIM59-IFT80 and these proteins makes it a promising target for drug development.

TRIM59-IFT80 has been shown to play a role in the regulation of gene expression and has been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that TRIM59-IFT80 is downregulated in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that targeting TRIM59-IFT80 may be a promising strategy for cancer treatment.

In addition to its potential role in cancer, TRIM59-IFT80 has also been linked to a number of neurodegenerative diseases. For example, studies have shown that TRIM59-IFT80 is involved in the regulation of neurotransmitter synthesis and release in the brain, and that it is involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

TRIM59-IFT80 has also been shown to be involved in the regulation of immune responses and has been linked to autoimmune disorders. For example, studies have shown that TRIM59-IFT80 is involved in the regulation of T cell development and function, and that it is involved in the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

Despite its potential role in a number of diseases, TRIM59-IFT80 has not yet been studied fully, and much more research is needed to fully understand its biology and potential as a drug target and biomarker. In the future, targeting TRIM59-IFT80 may be a promising strategy for the treatment of a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Protein Name: TRIM59-IFT80 Protein

The "TRIM59-IFT80 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM59-IFT80 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets